S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008

Im Auftrag der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Krebsgesellschaft (DKG) in Zusammenarbeit mit der:

Deutschen Gesellschaft für Viszeralchirurgie (DGVC) Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO) Deutschen Gesellschaft für Pathologie (DGP) Deutschen Gesellschaft für Radioonkologie (DEGRO) Chirurgischen Arbeitsgemeinschaft Onkologie (CAO-V) Deutschen Röntgengesellschaft (DRG) Deutschen Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) Deutschen Gesellschaft für Koloproktologie (DGK) Vereinigung für Stomaträger und für Menschen mit Darmkrebs (Deutsche ILCO) Deutschen Morbus Crohn/Colitis ulcerosa Vereinigung (DCCV) Deutschen Gesellschaft für Innere Medizin (DGIM) Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften e. V. (AWMF)

mit Unterstützung der Deutschen Krebshilfe e. V.

Leitung: W. Schmiegel unter Mitarbeit von: A. Reinacher-Schick, C. Pox, I. Kopp

Literatur

• 1 Schmiegel W. et al . Kolorektales Karzinom: Prävention und Früherkennung in der asynmptomatischen Bevölkerung – Vorsorge bei Risikopatienten – Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen.  Z Gastroenterol. 2000;  38 49-76
• 2 Schmiegel W. et al . S3-Guidelines Conference “Colorectal Carcinom” 2004.  Z Gastroenterol. 2004;  42 (10) 1129-1177
• 108 Lieberman D A, Weiss D G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.  N Engl J Med. 2001;  345 (8) 555-560 (EBM-Grad: III b)
• 110 Imperiale T F. et al . Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.  N Engl J Med. 2000;  343 (3) 169-174 (EBM-Grad: III b)
• 123 Pickhardt P J. et al . Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.  N Engl J Med. 2003;  349 (23) 2191-2200 (EBM-Grad: I b)
• 281 Hamilton S R, Aaltonen L A. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classifecation of Tumours Lyon; IARC Press 2000
• 312 Kiesslich R. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 (4) 880-888 (EBM-Grad: I b)
• 313 Rex D K. et al . Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer.  Am J Gastroenterol. 2002;  97 (6) 1296-1308
• 314 Barclay R L. et al . Colonoscopic withdrawal times and adenoma detection during screening colonoscopy.  N Engl J Med. 2006;  355 (24) 2533-2541 (EBM-Grad: II b)
• 315 Simmons D T. et al . Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time.  Aliment Pharmacol Ther. 2006;  24 (6) 965-971 (EBM-Grad: III b)
• 316 Lieberman D. A call to action – measuring the quality of colonoscopy.  N Engl J Med. 2006;  355 (24) 2588-2589
• 317 Robertson D J. et al . Colorectal cancer in patients under close colonoscopic surveillance.  Gastroenterology. 2005;  129 (1) 34-41 (EBM-Grad: III b)
• 318 Hosokawa O. et al . Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer.  Endoscopy. 2003;  35 (6) 506-510 (EBM-Grad: III b)
• 319 Bressler B. et al . Colonoscopic miss rates for right-sided colon cancer: a population-based analysis.  Gastroenterology. 2004;  127 (2) 452-456 (EBM-Grad: III b)
• 320 Leaper M. et al . Reasons for failure to diagnose colorectal carcinoma at colonoscopy.  Endoscopy. 2004;  36 (6) 499-503 (EBM-Grad: III b)
• 321 Pabby A. et al . Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial.  Gastrointest Endosc. 2005;  61 (3) 385-91 (EBM-Grad: III b)
• 322 Cotton P B. et al . Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia.  Jama. 2004;  291 (14) 1713-1719 (EBM-Grad: I b)
• 323 Rockey D C. et al . Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison.  Lancet. 2005;  365 (9456) 305-311 (EBM-Grad: I b)
• 324 Halligan S. et al . CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting.  Radiology. 2005;  237 (3) 893-904 (EBM-Grad: I a)
• 325 Mulhall B P, Veerappan G R, Jackson J L. Meta-analysis: computed tomographic colonography.  Ann Intern Med. 2005;  142 (8) 635-650 (EBM-Grad: I a)
• 326 Johnson C D. et al . Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps.  Clin Gastroenterol Hepatol. 2004;  2 (4) 314-321 (EBM-Grad: I b)
• 327 Purkayastha S. et al . Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a meta-analysis.  Clin Radiol. 2005;  60 (9) 980-989 (EBM-Grad: II a)
• 328 Hartmann D. et al . Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy.  Radiology. 2006;  238 (1) 143-149 (EBM-Grad: II b)
• 329 Florie J. et al . MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer.  Radiology. 2007;  243 (1) 122-131 (EBM-Grad: I b)
• 330 Morrin M M. et al . Virtual colonoscopy: a kinder, gentler colorectal cancer screening test?.  Lancet. 1999;  354 (9184) 1048-1049
• 331 Morrin M M. et al . Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions.  Dis Colon Rectum. 2000;  43 (3) 303-311 (EBM-Grad: IV)
• 332 Neri E. et al . Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy.  Radiology. 2002;  223 (3) 615-619 (EBM-Grad: IV)
• 333 Hartmann D. et al . Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon.  Endoscopy. 2005;  37 (9) 816-820 (EBM-Grad: IV)
• 334 Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield.  Gastrointest Endosc. 2004;  60 (3) 408-413 (EBM-Grad: III b)
• 335 Karajeh M A, Sanders D S, Hurlstone D P. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients.  Endoscopy. 2006;  38 (3) 226-230 (EBM-Grad: III b)
• 336 Hurlstone D P. et al . The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-bac” endoscopic study.  Am J Gastroenterol. 2005;  100 (10) 2167-2173 (EBM-Grad: II b)
• 337 Hurlstone D P. et al . Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation.  Endoscopy. 2005;  37 (12) 1186-1192 (EBM-Grad: III b)
• 338 Lee J H. et al . Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine.  Am J Gastroenterol. 2003;  98 (6) 1284-1288 (EBM-Grad: II b)
• 339 Hurlstone D P. et al . Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy.  Gut. 2004;  53 (3) 376-380 (EBM-Grad: I b)
• 340 Trecca A. et al . Advanced diagnostic tools: virtual colonoscopy and magnifying chromoendoscopy.  Tech Coloproctol. 2004;  8 (Suppl 2) s279-s282
• 341 Lapalus M G. et al . Does chromoendoscopy with structure enhancement improve the colonoscopic adenoma detection rate?.  Endoscopy. 2006;  38 (5) 444-448 (EBM-Grad: I b)
• 342 Kudo S. et al . Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer.  World J Surg. 2000;  24 (9) 1081-1090,
• 343 Kiesslich R. et al . Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon.  Endoscopy. 2001;  33 (12) 1001-1006 (EBM-Grad: VI b)
• 344 Kudo S. et al . Pit pattern in colorectal neoplasia: endoscopic magnifying view.  Endoscopy. 2001;  33 (4) 367-373 (EBM-Grad: III b)
• 345 Brooker J C. et al . Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial.  Gastrointest Endosc. 2002;  56 (3) 333-338 (EBM-Grad: I b)
• 346 Eisen G M. et al . High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study.  Gastrointest Endosc. 2002;  55 (6) 687-694 (EBM-Grad: IV)
• 347 Tsuda S. et al . Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study.  Gut. 2002;  51 (4) 550-555 (EBM-Grad: II b)
• 348 Bianco M A. et al . Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery.  Endoscopy. 2006;  38 (5) 470-476 (EBM-Grad: IV)
• 349 Kato S. et al . Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions.  World J Gastroenterol. 2006;  12 (9) 1416-1420 (EBM-Grad: III b)
• 350 Hurlstone D P. et al . Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy.  Colorectal Dis. 2004;  6 (5) 369-375 (EBM-Grad: II b)
• 351 Hurlstone D P. et al . Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis.  Gut. 2004;  53 (2) 284-290 (EBM-Grad: II b)
• 352 Chiu H M. et al . A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia.  Gut. 2007;  56 (3) 373-379 (EBM-Grad: II b)
• 353 Dekker E. et al . Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis.  Endoscopy. 2007;  39 (3) 216-221 (EBM-Grad: II b)
• 354 Su M Y. et al . Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps.  Am J Gastroenterol. 2006;  101 (12) 2711-2716 (EBM-Grad: IV)
• 355 Kiesslich R. et al . Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo.  Gastroenterology. 2004;  127 (3) 706-713 (EBM-Grad: IV)
• 356 Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies.  Dis Colon Rectum. 1986;  29 (12) 825-830 (EBM-Grad: IV)
• 357 Reiertsen O. et al . Complications of fiberoptic gastrointestinal endoscopy – five years’ experience in a central hospital.  Endoscopy. 1987;  19 (1) 1-6 (EBM-Grad: IV)
• 358 Waye J D, Lewis B S, Yessayan S. Colonoscopy: a prospective report of complications.  J Clin Gastroenterol. 1992;  15 (4) 347-351 (EBM-Grad: IV)
• 359 Waye J D, Kahn O, Auerbach M E. Complications of colonoscopy and flexible sigmoidoscopy.  Gastrointest Endosc Clin N Am. 1996;  6 (2) 343-377 (EBM-Grad: IV)
• 360 Hsieh Y H. et al . Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study.  Hepatogastroenterology. 2001;  48 (41) 1379-1382 (EBM-Grad: I b)
• 361 Karita M, Cantero D, Okita K. Endoscopic diagnosis and resection treatment for flat adenoma with severe dysplasia.  Am J Gastroenterol. 1993;  88 (9) 1421-1423 (EBM-Grad: IV)
• 362 Kudo S. et al . Endoscopic diagnosis and treatment of early colorectal cancer.  World J Surg. 1997;  21 (7) 694-701
• 363 Heldwein W. et al . The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies.  Endoscopy. 2005;  37 (11) 1116-1122 (EBM-Grad: III b)
• 364 Di Giorgio P. et al . Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study.  Endoscopy. 2004;  36 (10) 860-863 (EBM-Grad: I b)
• 365 Dobrowolski S. et al . Prophylactic submucosal saline-adrenaline injection in colonoscopic polypectomy: prospective randomized study.  Surg Endosc. 2004;  18 (6) 990-993 (EBM-Grad: I b)
• 366 Katsinelos P. et al . Endoloop-assisted polypectomy for large pedunculated colorectal polyps.  Surg Endosc. 2006;  20 (8) 1257-1261 (EBM-Grad: IV)
• 367 Paspatis G A. et al . A prospective, randomized comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of postpolypectomy bleeding in large colonic polyps.  Am J Gastroenterol. 2006;  101 (12) 2805; quiz 2913 (EBM-Grad: I b)
• 368 Shioji K. et al . Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy.  Gastrointest Endosc. 2003;  57 (6) 691-694 (EBM-Grad: I b)
• 369 Shiffman M L, Farrel M T, Yee Y S. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS.  Gastrointest Endosc. 1994;  40 (4) 458-462
• 370 Hui A J. et al . Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases.  Gastrointest Endosc. 2004;  59 (1) 44-48 (EBM-Grad: IV)
• 371 Yousfi M. et al . Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin.  Am J Gastroenterol. 2004;  99 (9) 1785-1789 (EBM-Grad: III b)
• 372 Ernst A. et al . Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans.  Chest. 2006;  129 (3) 734-737 (EBM-Grad: IV)
• 373 Hurlstone D P. et al . A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery.  Colorectal Dis. 2005;  7 (4) 339-344 (EBM-Grad: IV)
• 374 Gondal G. et al . Biopsy of colorectal polyps is not adequate for grading of neoplasia.  Endoscopy. 2005;  37 (12) 1193-1197 (EBM-Grad: IV)
• 375 Waye J D. et al . Small colon polyps.  Am J Gastroenterol. 1988;  83 (2) 120-122
• 376 O’Brien M J. et al . The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas.  Gastroenterology. 1990;  98 (2) 371-379
• 377 Nusko G. et al . Risk of invasive carcinoma in colorectal adenomas assessed by size and site.  Int J Colorectal Dis. 1997;  12 (5) 267-271
• 378 Bond J H. Clinical relevance of the small colorectal polyp.  Endoscopy. 2001;  33 (5) 454-457
• 379 Arumugam P J. et al . Severe dysplastic lesions in the colon – how aggressive should we be?.  Colorectal Dis. 2002;  4 (5) 345-347
• 380 Gschwantler M. et al . High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics.  Eur J Gastroenterol Hepatol. 2002;  14 (2) 183-188 (EBM-Grad: IV)
• 381 Burton S. et al . Reliability of pre-operative biopsies in the histological grading of colorectal adenocarcinomas.  Ann R Coll Surg Engl. 2003;  85 (1) 23-25 (EBM-Grad: IV)
• 382 Jass J R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.  Histopathology. 2007;  50 (1) 113-130
• 383 Makinen M J. Colorectal serrated adenocarcinoma.  Histopathology. 2007;  50 (1) 131-150
• 384 Deinlein P. et al . Risk factors for lymphatic metastasis from pT1 colorectal adenocarcinoma.  Pathologe. 2003;  24 (5) 387-393 (EBM-Grad: III a)
• 385 Hermanek P. Polypectomy in the colorectum: histological and oncological aspects.  Endoscopy. 1983;  15 158-161
• 386 Kikuchi R. et al . Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines.  Dis Colon Rectum. 1995;  38 (12) 1286-1295
• 387 Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma.  Dis Colon Rectum. 2002;  45 (5) 628-634 (EBM-Grad: IV)
• 388 Fruhmorgen P. et al . Endoscopic Therapy of Early Colorectal Cancer (pT1) – A Prospective Study.  Z Gastroenterol. 2003;  41 (8) 703-710,
• 39 Frühmorgen P. et al .Kolorektale Polypen, in Empfehlungen der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) für die Durchführung endoskopischer Untersuchungen. 2000: 127-134
• 390 Okabe S. et al . Lymph node metastasis in T 1 adenocarcinoma of the colon and rectum.  J Gastrointest Surg. 2004;  8 (8) 1032-1039; discussion 1039 – 1040 (EBM-Grad: IV)
• 391 Yamamoto S. et al . The risk of lymph node metastasis in T 1 colorectal carcinoma.  Hepatogastroenterology. 2004;  51 (58) 998-1000 (EBM-Grad: : IV)
• 392 Hassan C. et al . Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis.  Dis Colon Rectum. 2005;  48 (8) 1588-1596 (EBM-Grad: III b)
• 393 Ueno H. et al . Risk factors for an adverse outcome in early invasive colorectal carcinoma.  Gastroenterology. 2004;  127 (2) 385-394 (EBM-Grad: III b)
• 394 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1 2002.  Gastrointest Endosc. 2003;  58 (6 Suppl) S3-S43
• 395 Nascimbeni R. et al . Risk of lymph node metastasis in T 1 carcinoma of the colon and rectum.  Dis Colon Rectum. 2002;  45 (2) 200-206 (EBM-Grad: IV)
• 396 Seitz U. et al . Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature.  Dis Colon Rectum. 2004;  47 (11) 1789-1796; discussion 1796 – 1797 (EBM-Grad: IV)
• 397 Provenzale D. et al . Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps.  Ann Intern Med. 1990;  113 760-763 (EBM-Grad: IV)
• 398 Rex D K. et al . Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects.  Gastroenterology. 1992;  102 317-319 (EBM-Grad: IV)
• 399 Sciallero S. et al . Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas.  Gastrointest Endosc. 1997;  46 (2) 124-130 (EBM-Grad: IV)
• 400 Koide N. et al . A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up.  Endoscopy. 2002;  34 (6) 499-502 (EBM-Grad: IV)
• 401 Bressler B. et al . Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis.  Gastroenterology. 2007;  132 (1) 96-102 (EBM-Grad: III b)
• 402 Sawhney M S. et al . Microsatellite instability in interval colon cancers.  Gastroenterology. 2006;  131 (6) 1700-1705 (EBM-Grad: IV)
• 403 Winawer S J. et al . Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.  Gastroenterology. 2006;  130 (6) 1872-1885
• 404 Higaki S. et al . Long-term follow-up of large flat colorectal tumors resected endoscopically.  Endoscopy. 2003;  35 (10) 845-849 (EBM-Grad: IV)
• 405 Regula J. et al . Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study.  Endoscopy. 2003;  35 (3) 212-218 (EBM-Grad: IV)
• 406 Seitz U. et al . Long-term results of endoscopic removal of large colorectal adenomas.  Endoscopy. 2003;  35 (8) S41-S44 (EBM-Grad: IV)
• 407 Boix J. et al . Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?.  Dig Dis Sci. 2007;  52 (3) 840-844 (EBM-Grad: IV)
• 408 Baron J A. et al . A randomized trial of aspirin to prevent colorectal adenomas.  N Engl J Med. 2003;  348 (10) 891-899 (EBM-Grad: I b)
• 409 Benamouzig R. et al . Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.  Gastroenterology. 2003;  125 (2) 328-336
• 410 Imperiale T F. Aspirin and the prevention of colorectal cancer.  N Engl J Med. 2003;  348 (10) 879-880
• 411 Arber N. et al . Celecoxib for the prevention of colorectal adenomatous polyps.  N Engl J Med. 2006;  355 (9) 885-895
• 412 Baron J A. et al . A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.  Gastroenterology. 2006;  131 (6) 1674-1682 (EBM-Grad: I b)
• 413 Bertagnolli M M. et al . Celecoxib for the prevention of sporadic colorectal adenomas.  N Engl J Med. 2006;  355 (9) 873-884 (EBM-Grad: I b)
• 414 Bresalier R S. et al . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.  N Engl J Med. 2005;  352 (11) 1092-102 (EBM-Grad: I b)
• 415 Solomon S D. et al . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.  N Engl J Med. 2005;  352 (11) 1071-1080 (EBM-Grad: I b)
• 416 Psaty B M, Potter J D. Risks and benefits of celecoxib to prevent recurrent adenomas.  N Engl J Med. 2006;  355 (9) 950-952
• 417 Weingarten M A, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.  Cochrane Database Syst Rev. 2005;  3 CD003548 (EBM-GradI a)
• 421 NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.  Jama. 1990;  264 (11) 1444-1450
• 513 Compton C. et al . American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.  Cancer. 2000;  88 (7) 1739-1757
• 519 Le Voyer T E. et al . Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.  J Clin Oncol. 2003;  21 (15) 2912-2919
• 527 Iwashyna T J, Lamont E B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.  J Clin Oncol. 2002;  20 (19) 3992-3998
• 528 Lonardi S, Stefani M, Jirillo A, Ghiotto C. et al . Benefit of fluorouracil and folinic acid adjuvant in colon cancer. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 13 564
• 529 Sargent D J. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 (15) 1091-1097
• 530 Popescu R A. et al . Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.  J Clin Oncol. 1999;  17 (8) 2412-2418
• 531 Goldberg R M, Tabah-Fisch I, Bleiberg H. et al . Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.  J Clin Oncol. 2006;  24 (25) 4085-4091 (EBM-Grad: I b)
• 532 Fata F. et al . Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.  Cancer. 2002;  94 (7) 1931-1938
• 533 Francini G. et al . Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.  Gastroenterology. 1994;  106 (4) 899-906
• 534 O’Connell M J. et al . Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.  J Clin Oncol. 1997;  15 (1) 246-250,
• 535 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis.  Dis Colon Rectum. 1997;  40 (1) 35-41
• 536 Gill S. et al . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.  J Clin Oncol. 2004;  22 (10) 1797-1806 (EBM-Grad: I a)
• 537 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.  Lancet. 1995;  345 (8955) 939-944
• 538 Figueredo A. et al . Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.  Cancer Prev Control. 1997;  1 (5) 379-392
• 539 Efficacy of adjuvant fluorouracil and folinic acid in B 2 colon cancer. International Multicentre Pooled Analysis of B 2 Colon Cancer Trials (IMPACT B 2) Investigators.  J Clin Oncol. 1999;  17 (5) 1356-1363
• 540 Mamounas E. et al . Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).  J Clin Oncol. 1999;  17 (5) 1349-1355
• 541 Benson 3 rd A B. et al . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.  J Clin Oncol. 2004;  22 (16) 3408-3419 (EBM-Grad: I a)
• 542 Quasar Collaborative G. et al . Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.  Lancet. 2007;  370 (9604) 2020-2029 (EBM-Grad: I b)
• 543 Gramont de A, Boni C, Navarro M. et al . Oxaliplatin/ 5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4007
• 544 Moertel C G. et al . Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B 2 colon cancer.  J Clin Oncol. 1995;  13 (12) 2936-2943
• 545 Taal B G, Van Tinteren H, Zoetmulder F A. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.  Br J Cancer. 2001;  85 (10) 1437-1443
• 546 Schrag D. et al . Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.  J Clin Oncol. 2002;  20 (19) 3999-4005
• 547 Merkel S. et al . High-risk groups of patients with Stage II colon carcinoma.  Cancer. 2001;  92 (6) 1435-1443
• 548 Petersen V C. et al . Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer.  Gut. 2002;  51 (1) 65-69
• 549 Morris M. et al . Population-based study of prognostic factors in stage II colonic cancer.  Br J Surg. 2006;  93 (7) 866-871 (EBM-Grad: IV)
• 550 Burdy G. et al . Identifying patients with T 3-T4 node-negative colon cancer at high risk of recurrence.  Dis Colon Rectum. 2001;  44 (11) 1682-1688
• 551 Jestin P. et al . Emergency surgery for colonic cancer in a defined population.  Br J Surg. 2005;  92 (1) 94-100 (EBM-Grad: IV)
• 552 McArdle C S, McMillan D C, Hole D J. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer.  Br J Surg. 2006;  93 (4) 483-488 (EBM-Grad: IV)
• 553 Caplin S. et al . For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.  Cancer. 1998;  83 (4) 666-672
• 554 George S. et al . Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists.  Br J Cancer. 2006;  95 (7) 841-847 (EBM-Grad: II b)
• 555 Chen S L, Bilchik A J. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study.  Ann Surg. 2006;  244 (4) 602-10 (EBM-Grad: IV)
• 556 Moertel C G. et al . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.  N Engl J Med. 1990;  322 (6) 352-358
• 557 Hermanek P, Hutter R V, Sobin L H. Prognostic grouping: the next step in tumor classification.  J Cancer Res Clin Oncol. 1990;  116 (5) 513-516
• 558 Martinez-Lopez E. et al . Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer.  Gastroenterology. 1998;  114 (6) 1180-1187
• 559 Ogunbiyi O A. et al . Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator.  J Clin Oncol. 1998;  16 (2) 427-433
• 560 Jernvall P. et al . Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.  Br J Cancer. 1999;  79 (5 – 6) 903-908
• 561 Font A. et al . Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.  Dis Colon Rectum. 2001;  44 (4) 549-557
• 562 Diep C B. et al . Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients.  J Clin Oncol. 2003;  21 (5) 820-829
• 563 Carethers J M. et al . Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.  Gastroenterology. 1998;  114 (6) 1188-1195
• 564 Lanza G. et al . Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.  J Clin Oncol. 2006;  24 (15) 2359-2367 (EBM-Grad: II c)
• 565 Sinicrope F A. et al . Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.  Gastroenterology. 2006;  131 (3) 729-737 (EBM-Grad: II c)
• 566 Araujo S E. et al . DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data.  Dis Colon Rectum. 2007;  50 (11) 1800-1810 (EBM-Grad: I a)
• 567 Ribic C M. et al . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.  N Engl J Med. 2003;  349 (3) 247-257
• 568 Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.  Clin Colorectal Cancer. 2001;  1 (2) 104-109
• 569 Andre T. et al . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  350 (23) 2343-2351 (EBM-Grad: I b)
• 570 Kuebler J P. et al . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.  J Clin Oncol. 2007;  25 (16) 2198-2204 (EBM-Grad: I b)
• 571 Schmoll H J. et al . Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.  J Clin Oncol. 2007;  25 (1) 102-109 (EBM-Grad: I b)
• 572 Van Cutsem E, Labianca R, Hossfeld D. et al . PETACC 3, Randomized phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 8
• 573 Ychou M, Raoul J-L, Douillard J. et al . For the GI Group of the FNCLCC and the FFCD. A phase III randomized trial of LV 5FU2 +CPT-11 vs. LV 5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02 /FFCD9802). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 3502
• 574 Saltz L B. et al . Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89 803.  J Clin Oncol. 2007;  25 (23) 3456-3461 (EBM-Grad: I b)
• 575 Twelves C. et al . Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 (26) 2696-2704 (EBM-Grad: I b)
• 576 Lembersky B C. et al . Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.  J Clin Oncol. 2006;  24 (13) 2059-2064 (EBM-Grad: I b)
• 577 Sakamoto J. et al . Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.  J Clin Oncol. 2004;  22 (3) 484-92 (EBM-Grad: I a)
• 578 Andre T, Quinaux E, Louvet C. et al . GERCOR, Updated results at 6 year of the GERCOR C 96.1 phase III study comparing LV 5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B 2 and C colon cancer patients. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 3522
• 579 Carrato A, Kohne C, Bedenne  L. et al . for AIO/CAO, FFCD, TTD, EORTC, Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. ASCO Annual Meeting Proceedings.  J of Clin Oncol. 2006;  24 (No 18S) 3563
• 580 Andre T. et al . Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.  J Clin Oncol. 2003;  21 (15) 2896-2903 (EBM-Grad: I b)
• 581 Arkenau H AT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.  Int J Colorectal Dis. 2005;  20 (3) 258-261 (EBM-Grad: I b)
• 582 Chau I. et al . A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.  Ann Oncol. 2005;  16 (4) 549-557 (EBM-Grad: I b)
• 583 Poplin E A. et al . Phase III Southwest Oncology Group 9415 /Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.  J Clin Oncol. 2005;  23 (9) 1819-1825 (EBM-Grad: I b)
• 584 O’Connell M J. et al . Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.  J Clin Oncol. 1998;  16 (1) 295-300,
• 585 Haller D G. et al . Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.  J Clin Oncol. 2005;  23 (34) 8671-8678 (EBM-Grad: I b)
• 586 Engelen S M, Beets G L, Beets-Tan R G. Role of preoperative local and distant staging in rectal cancer.  Onkologie. 2007;  30 (3) 141-145 (EBM-Grad: III a)
• 587 Beets-Tan R G. et al . Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery.  Lancet. 2001;  357 (9255) 497-504
• 588 MERCURY Study Group . Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.  Radiology. 2007;  243 (1) 132-139 (EBM-Grad: I b)
• 589 Junginger T. et al . Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication.  Zentralbl Chir. 2006;  131 (4) 275-284
• 590 Smith N, Brown G. Preoperative staging of rectal cancer.  Acta Oncol. 2008;  47 20-31
• 591 Kapiteijn E. et al . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.  N Engl J Med. 2001;  345 (9) 638-646
• 592 Rodel C, Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer.  Recent Results Cancer Res. 2005;  165 221-230
• 593 Peeters K C. et al . The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.  Ann Surg. 2007;  246 (5) 693-701 (EBM-Grad: I b)
• 594 Folkesson J. et al . Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.  J Clin Oncol. 2005;  23 (24) 5644-5650 (EBM-Grad: I b)
• 595 Baxter N N, Garcia-Aguilar J. Organ preservation for rectal cancer.  J Clin Oncol. 2007;  25 (8) 1014-1020 (EBM-Grad: IV)
• 596 Rengan R. et al . Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?.  J Clin Oncol. 2005;  23 (22) 4905-4912 (EBM-Grad: IV)
• 597 Colorectal Cancer Collaborative Group . Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.  Lancet. 2001;  358 (9290) 1291-1304
• 598 Camma C. et al . Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.  Jama. 2000;  284 (8) 1008-1015
• 599 Frykholm G J, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects.  Dis Colon Rectum. 1993;  36 (6) 564-572
• 600 Sauer R. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  351 (17) 1731-1740 (EBM-Grad: I b)
• 601 Marijnen C A. et al . Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.  J Clin Oncol. 2005;  23 (9) 1847-1858 (EBM-Grad: II b)
• 602 Peeters K C. et al . Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study.  J Clin Oncol. 2005;  23 (25) 6199-6206
• 603 Sebag-Montefiore D, Steele R, Quirke P. et al . For the NCRI colorectal cancer study group and CRO7 participants. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR 07 randomised trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3511
• 604 Bujko K. et al . Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.  Radiother Oncol. 2004;  72 (1) 15-24 (EBM-Grad: I b)
• 605 Bujko K. et al . Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.  Br J Surg. 2006;  93 (10) 1215-1223 (EBM-Grad: I b)
• 606 Marijnen C A. et al . No downstaging after short-term preoperative radiotherapy in rectal cancer patients.  J Clin Oncol. 2001;  19 (7) 1976-1984
• 607 Bosset J F. et al . Chemotherapy with preoperative radiotherapy in rectal cancer.  N Engl J Med. 2006;  355 (11) 1114-1123 (EBM-Grad: I b)
• 608 Gerard J P. et al . Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T 3 – 4 rectal cancers: results of FFCD 9203.  J Clin Oncol. 2006;  24 (28) 4620-4625 (EBM-Grad: I b)
• 609 Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients.  Strahlenther Onkol. 2007;  183 (5) 227-235
• 610 Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group.  N Engl J Med. 1985;  312 (23) 1465-1472
• 611 Krook J E. et al . Effective surgical adjuvant therapy for high-risk rectal carcinoma.  N Engl J Med. 1991;  324 (11) 709-715
• 612 Merkel S, Mansmann U, Siassi M. et al . The prognostic inhomogeneity in pT3 rectal carcinomas.  Int J Colorectal Dis. 2001;  16 298-304
• 613 Gunderson L L, Sargent DJ, Tepper J E. et al . Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.  Int J Radiat Oncol Biol Phys. 2002;  54 386-396
• 614 Marijnen C A. et al . Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial.  Int J Radiat Oncol Biol Phys. 2003;  55 (5) 1311-1320
• 615 O’Connell M J. et al . Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.  N Engl J Med. 1994;  331 502-507
• 616 Smalley S R. et al . Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.  J Clin Oncol. 2006;  24 (22) 3542-3547 (EBM-Grad: I b)
• 617 Tepper J E. et al . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114.  J Clin Oncol. 2002;  20 (7) 1744-1750
• 618 Lee J H. et al . Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.  J Clin Oncol. 2002;  20 (7) 1751-1758
• 619 Kim B ITK, Lee J. et al . Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A final report. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4050
• 620 Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer.  Surg Oncol. 2004;  13 (2 – 3) 93-101
• 621 Akasu T. et al . Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.  Jpn J Clin Oncol. 2006;  36 (4) 237-244 (EBM-Grad: I b)
• 622 Collette L BJ, den Dulk M. et al . Patients with curative resection of cT3 – 4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.  J Clin Oncol. 2007;  25 4379-4386 (EBM-Grad: III b)
• 623 Lehnert T KH, Duck M. et al . Sequential hepatic and pulmonary resections for metastatic colorectal cancer.  Br J Surg. 1999;  86 241-243
• 624 Saito Y. et al . Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment.  J Thorac Cardiovasc Surg. 2002;  124 (5) 1007-1013
• 625 Pfannschmidt J. et al . Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients.  J Thorac Cardiovasc Surg. 2003;  126 (3) 732-739
• 626 Lee W S. et al . Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival.  Int J Colorectal Dis. 2007;  22 (6) 699-704 (EBM-Grad: III b)
• 627 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.  Ann Thorac Surg. 2007;  84 (1) 324-338 (EBM-Grad: II a)
• 628 Poston G J. et al . OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.  J Clin Oncol. 2005;  23 (28) 7125-7134 (EBM-Grad: II a)
• 629 Nordlinger B. et al . Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie.  Cancer. 1996;  77 (7) 1254-1262
• 630 Fong Y. et al . Liver resection for colorectal metastases.  J Clin Oncol. 1997;  15 (3) 938-946
• 631 Scheele J. et al . Resection of colorectal liver metastases. What prognostic factors determine patient selection?.  Chirurg. 2001;  72 (5) 547-560
• 632 Kato T. et al . Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.  Dis Colon Rectum. 2003;  46 (10 Suppl) S22-S31
• 633 Fong Y FJ, Sun R L, Brennan M F. et al . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.  Ann Surg. 1999;  230 (3) 309-318; discussion 318 – 321
• 634 Joyce D L. et al . Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases.  Arch Surg. 2006;  141 (12) 1220-1226; discussion 1227 (EBM-Grad: II b)
• 635 Selzner M. et al . Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?.  Ann Surg. 2004;  240 (6) 1027-1034; discussion 1035 – 1036 (EBM-Grad: II b)
• 636 Amthauer H. et al . Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.  Nuklearmedizin. 2006;  45 (4) 177-184 (EBM-Grad: II b)
• 637 Taylor R A, Turoto S, Akhurst T J. et al . Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score.  Gastrointestinal Cancers Symposium. 2007;  Abstract No 240
• 638 Nordlinger B. et al . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40 983): a randomised controlled trial.  Lancet. 2008;  371 (9617) 1007-1016 (EBM-Grad: I b)
• 639 Leonard G D, Brenner B, Kemeny N E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.  J Clin Oncol. 2005;  23 (9) 2038-2048 (EBM-Grad: I a)
• 640 Lorenz M. et al . Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.  Zentralbl Chir. 2003;  128 (2) 87-94
• 641 Wein A. et al . Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.  Oncology. 2003;  64 (2) 131-138
• 642 Gruenberger B. et al . Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.  J Clin Oncol. 2008;  26 (11) 1830-1835 (EBM-Grad: II b)
• 643 Langer B, Bleiberg H, Labianca B. et al . Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial.  J Clin Oncol. 2002;  21 (No 18S) 592
• 644 Mitry E, Fields A, Bleiberg H. et al . Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3524
• 645 Portier G. et al . Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.  J Clin Oncol. 2006;  24 (31) 4976-4982 (EBM-Grad: II a)
• 646 Parks R. et al . Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.  J Am Coll Surg. 2007;  204 (5) 753-761; discussion 761 – 763 (EBM-Grad: III b)
• 647 Figueras J. et al . Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.  Br J Surg. 2001;  88 (7) 980-985
• 648 Scheithauer W. et al . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  Bmj. 1993;  306 (6880) 752-755
• 649 Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group.  J Clin Oncol. 1992;  10 (6) 904-911
• 650 Mattioli R. et al . High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.  Ann Oncol. 2005;  16 (7) 1147-1151 (EBM-Grad: IV)
• 651 Feliu J. et al . XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.  Br J Cancer. 2006;  94 (7) 969-975 (EBM-Grad: IV)
• 652 Sastre J. et al . Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.  J Clin Oncol. 2005;  23 (15) 3545-3551 (EBM-Grad: II b)
• 653 Barrueco J, Marshall J, Mitchell E. et al . Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients > 65 years compared with those > 65: THE BICC-C STUDY. ASCO ANNUAL MEETING PROCEEDINGS.  J Clin Oncol. 2007;  25 (No 18S) 4076
• 654 Folprecht G, Seymour M, Saltz L. et al . Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials.  J Clin Oncol. 2008;  26 1443-1451 (EBM-Grad: I a)
• 655 Grothey A. et al . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.  J Clin Oncol. 2004;  22 (7) 1209-1214 (EBM-Grad: IV)
• 656 Giacchetti S. et al . Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.  Ann Oncol. 1999;  10 (6) 663-669
• 657 Falcone A. et al . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.  J Clin Oncol. 2007;  25 (13) 1670-1676 (EBM-Grad: I b)
• 658 Van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4000
• 659 Van Cutsem E, Lang I, D’haens G. et al . KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2008;  26 (No 18S) 2
• 660 Folprecht G. et al . Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.  Ann Oncol. 2005;  16 (8) 1311-1319 (EBM-Grad: I a)
• 661 Souglakos J. et al . FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).  Br J Cancer. 2006;  94 (6) 798-805 (EBM-Grad: I b)
• 662 Saltz L B. et al . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.  J Clin Oncol. 2008;  26 (12) 2013-2019 (EBM-Grad: I b)
• 663 Aloia T. et al . Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 (31) 4983-4990 (EBM-Grad: IV)
• 664 Vauthey J N. et al . Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 (13) 2065-2072 (EBM-Grad: II b)
• 665 Benoist S. et al . Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.  J Clin Oncol. 2006;  24 (24) 3939-3945 (EBM-Grad: IV)
• 666 Solbiati L LT, Goldberg S N. et al . Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients.  Radiology. 2001;  221 159-166
• 667 Vogl T J, Straub R, Eichler K. et al . Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions).  Radiology. 2002;  225 367-377
• 668 Kerr D, McArdle C, Ledermann J. et al . Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: amulticentre randomised trial.  Lancet. 2003;  361 368-373
• 669 Gray B. et al . Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.  Ann Oncol. 2001;  12 (12) 1711-1720
• 670 Lim L. et al . A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.  BMC Cancer. 2005;  5 132 (EBM-GradII c)
• 671 Mancini R. et al . A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i. v. chemotherapy: preliminary results on toxicity and response rates.  In Vivo. 2006;  20 (6A) 711-714 (EBM-Grad: IV)
• 672 Welsh J S, Kennedy A S, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.  Int J Radiat Oncol Biol Phys. 2006;  66 (Suppl 2) S62-S73 (EBM-Grad: III a)
• 673 Koopman M. et al . Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.  Lancet. 2007;  370 (9582) 135-142 (EBM-Grad: I b)
• 674 Schmoll H J, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?.  Lancet. 2007;  370 (9582) 105-107
• 675 Seymour M T. et al . Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.  Lancet. 2007;  370 (9582) 143-152 (EBM-Grad: I b)
• 676 Dy G K. et al . Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N 9741.  J Clin Oncol. 2007;  25 (23) 3469-3474 (EBM-Grad: IV)
• 677 Petrelli N. et al . The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.  J Clin Oncol. 1989;  7 (10) 1419-1426
• 678 Poon M A. et al . Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.  J Clin Oncol. 1989;  7 (10) 1407-1418
• 679 Lokich J J. et al . A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.  J Clin Oncol. 1989;  7 (4) 425-432
• 680 Gramont de A. et al . Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.  J Clin Oncol. 1997;  15 (2) 808-815
• 681 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.  J Clin Oncol. 1998;  16 (1) 301-308
• 682 Clarke D E, Raffin T A. Infectious complications of indwelling long-term central venous catheters.  Chest. 1990;  97 (4) 966-972
• 683 Prandoni P. et al . Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216).  Haemostasis. 1990;  20 (Suppl 1) 220-223
• 684 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21 (19) 3665-3675
• 685 Liu G. et al . Patient preferences for oral versus intravenous palliative chemotherapy.  J Clin Oncol. 1997;  15 (1) 110-115
• 686 Borner M M. et al . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.  Eur J Cancer. 2002;  38 (3) 349-358
• 687 Twelves C. et al . A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.  Ann Oncol. 2006;  17 (2) 239-245 (EBM-Grad: II b)
• 688 Van Cutsem E. et al . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.  J Clin Oncol. 2001;  19 (21) 4097-4106 (EBM-Grad: I b)
• 689 Hoff P M. et al . Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.  J Clin Oncol. 2001;  19 (8) 2282-2292 (EBM-Grad: I b)
• 690 Van Cutsem E. et al . Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.  Br J Cancer. 2004;  90 (6) 1190-1197 (EBM-Grad: I a)
• 691 Kohne C H. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.  Ann Oncol. 2002;  13 (2) 308-317
• 692 Gramont de A. et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 (16) 2938-2947
• 693 Giacchetti S. et al . Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.  J Clin Oncol. 2006;  24 (22) 3562-3569 (EBM-Grad: I b)
• 694 Giacchetti S. et al . Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 (1) 136-147 (EBM-Grad: I b)
• 695 Douillard J Y. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 (9209) 1041-1047 (EBM-Grad: I b)
• 696 Kohne C H. et al . Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40 986.  J Clin Oncol. 2005;  23 (22) 4856-4865 (EBM-Grad: I b)
• 697 Saltz L B. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.  N Engl J Med. 2000;  343 (13) 905-914
• 698 Tournigand C. et al . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.  J Clin Oncol. 2004;  22 (2) 229-237 (EBM-Grad: I b)
• 699 Colucci G. et al . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale.  J Clin Oncol. 2005;  23 (22) 4866-4875 (EBM-Grad: I b)
• 700 Goldberg R M. et al . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.  J Clin Oncol. 2004;  22 (1) 23-30 (EBM-Grad: I b)
• 701 Goldberg R M. et al . Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.  J Clin Oncol. 2006;  24 (21) 3347-3353 (EBM-Grad: I b)
• 702 Comella P. et al . Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i. v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i. v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.  Ann Oncol. 2005;  16 (6) 878-886 (EBM-Grad: I b)
• 703 Diaz-Rubio E. et al . Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.  J Clin Oncol. 2007;  25 (27) 4224-4230 (EBM-Grad: I b)
• 704 Porschen R. et al . Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.  J Clin Oncol. 2007;  25 (27) 4217-4223 (EBM-Grad: I b)
• 705 Cassidy J. et al . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.  J Clin Oncol. 2008;  26 (12) 2006-2012 (EBM-Grad: I b)
• 706 Fuchs C S. et al . Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.  J Clin Oncol. 2007;  25 (30) 4779-4786 (EBM-Grad: I b)
• 707 Kohne C H. et al . Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40 015.  Ann Oncol. 2008;  19 (5) 920-926 (EBM-Grad: I b)
• 708 Schmiegel W, Reinacher-Schick A, Freier W. et al . Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4034
• 709 Kabbinavar F F. et al . Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 (16) 3697-3705 (EBM-Grad: I b)
• 710 Hurwitz H. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 (23) 2335-2342 (EBM-Grad: I b)
• 711 Bokemeyer C, Bondarenko I, Makhson A. et al . Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4035
• 712 Folprecht G. et al . Cetuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.  Ann Oncol. 2006;  17 (3) 450-456 (EBM-Grad: IV)
• 713 Tournigand C. et al . OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study.  J Clin Oncol. 2006;  24 (3) 394-400 (EBM-Grad: I b)
• 714 Maindrault-Goebel F, Lledo G, Chibaudel B. et al . Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4013
• 715 Maughan T S. et al . Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.  Lancet. 2003;  361 (9356) 457-464 (EBM-Grad: I b)
• 716 Labianca R IF, Cortesi E. et al . Italian Group for the Study of Digestive Tract Can, Alternating versus continuous “FOLFIR” in advanced colorectal cancer (ACC): A randomized “GISCA” trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3505
• 717 Cunningham D. et al . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 (9138) 1413-1418 (EBM-Grad: I b)
• 718 Rougier P. et al . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.  Lancet. 1998;  352 (9138) 1407-1412 (EBM-Grad: I b)
• 719 Rothenberg M L. et al . Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.  J Clin Oncol. 2003;  21 (11) 2059-2069 (EBM-Grad: I b)
• 720 Cunningham D. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 (4) 337-345 (EBM-Grad: I b)
• 721 Sobrero AF, Fehrenbacher L, Maurel J. et al . EPIC: Randomized Phase III trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer.  J Clin Oncol. 2008;  26 2311-2319 (EBM-Grad: I b)
• 722 Giantonio B J. et al . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E 3200.  J Clin Oncol. 2007;  25 (12) 1539-1544 (EBM-Grad: I b)
• 723 Rothenberg M L MN, Butts C. et al . Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4031
• 724 Eng C, Maurel J, Scheithauer W. et al . Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4003
• 725 Rao S. et al . Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.  Br J Cancer. 2004;  91 (5) 839-843 (EBM-Grad: IV)
• 726 Chong G. et al . Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.  Br J Cancer. 2005;  93 (5) 510-514 (EBM-Grad: IV)
• 727 Lim D H. et al . Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.  Cancer Chemother Pharmacol. 2005;  56 (1) 10-14 (EBM-Grad: IV)
• 728 Alliot C. Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.  Br J Cancer. 2006;  94 (6) 935-936; author reply 937
• 729 Lenz H J. et al . Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.  J Clin Oncol. 2006;  24 (30) 4914-4921 (EBM-Grad: II c)
• 730 Jonker D J, Karapetis C S, O’Callaghan J. et al . Cetuximab for the Treatment of Colorectal Cancer.  N Engl J Med. 2007;  357 2040-2048 (EBM-Grad: I b)
• 731 Lievre A. et al . KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.  J Clin Oncol. 2008;  26 (3) 374-379 (EBM-Grad: IV)
• 732 Hecht J R. et al . Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.  Cancer. 2007;  110 (5) 980-988 (EBM-Grad: IV)
• 733 Van Cutsem E. et al . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.  J Clin Oncol. 2007;  25 (13) 1658-1664 (EBM-Grad: I b)
• 734 Amado R, Wolf M, Peeters M. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.  J Clin Oncol. 2008;  26 1626-1634 (EBM-Grad: IV)
• 735 Lehnert T GM. Posterior pelvic exenteration in locoregional recurrence of rectal carcinoma – indications, technique and outcome.  Chirurg. 2001;  72 1393-1401
• 736 Shibata D, Paty P, Guillem J G. et al . Surgical management of isolatedretroperitoneal recurrences of colorectal carcinoma.  Dis Colon Rectum. 2002;  45 795-801
• 737 Koppe M J, Boerman O, Oyen W J. et al . Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.  Ann Surg. 2006;  243 (2) 212-222 (EBM-Grad: III a)
• 738 Verwaal V J, Ruth van S, Bree de E. et al . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
• 739 Wu J S, Wong R, Johnston M. et al . Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.  Int J Radiat Oncol Biol Phys. 2003;  55 594-605
• 740 Farnell G F, Buckner J, Cascino T L. et al . Brain metastases from colorectalcarcinoma. The long term survivors.  Cancer. 1996;  78 711-716
• 771 Schoeggl A, Kitz K, Reddy M. et al . Stereotactic radiosurgery for brain metastases from colorectal cancer.  Int J Colorectal Dis. 2002;  17 150-155

1b * Studie bislang nur in Abstraktform publiziert.